Monitor for updates on the strategic review process and any potential partnerships or transactions. The FDA's requirement for a randomized controlled trial presents significant challenges that could impact the development path and valuation of PBFT02.
Price Chart
Executive Summary
Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing reduced brain atrophy and stabilized plasma neurofilament levels in FTD-GRN patients. The FDA indicated a randomized controlled trial is required for registration, leading the company to evaluate strategic alternatives to maximize shareholder value.
Key Facts
- PBFT02-treated patients with CDR score 1 showed 64% reduction in whole brain atrophy and 54% reduction in frontotemporal cortex atrophy compared to natural history
- Plasma NfL levels among PBFT02-treated patients showed average reduction of 1.0 pg/mL at 12 months
- FDA indicated a randomized controlled registrational study design is required for PBFT02 in FTD-GRN indication
- Company has initiated a review of strategic alternatives including merger, acquisition, or sale of assets
- Cash runway expected through 1Q 2027
Financial Impact
No direct financial impact disclosed, but strategic review could lead to significant changes in company direction or valuation
Risk Factors
- FDA's requirement for randomized controlled trial presents ethical, logistical, and financial challenges
- Strategic review may not result in any transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-045219 |
| Document: tm2612152d1_8k.htm | 0001104659-26-045219 |
| Document: tm2612152d1_ex99-1.htm | 0001104659-26-045219 |
| Document: 0001104659-26-045219-index-headers.html | 0001104659-26-045219 |
| Document: 0001104659-26-045219-index.html | 0001104659-26-045219 |
| Document: 0001104659-26-045219.txt | 0001104659-26-045219 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | S-4/A / 425 | $4.75 $5.00 | ▼ −5.26% | ▼ −6.41% | $4.12 (+13.26%) |
Sep 3, 2026 29d ago | 8-K | $4.75 $5.00 | ▲ +5.26% | ▲ +6.41% | $4.12 (−13.26%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.12 (+4.85%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.12 (+4.85%) |
Jun 24, 2026 14w ago | 8-K | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.12 (+4.85%) |
May 27, 2026 18w ago | 8-K | $5.71 $6.00 | ▼ −5.08% | ▼ −4.76% | $4.12 (+27.85%) |
Apr 20, 2026 23w ago | 8-K | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.12 (−34.08%) |
Apr 20, 2026 23w ago | Press Release | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.12 (−34.08%) |
Apr 7, 2026 25w ago | DEFA14A | $8.22 $10.86 | ▲ +32.20% | ▲ +26.87% | $4.12 (−49.85%) |
Mar 3, 2026 30w ago | Press Release | $8.00 $8.51 | ▲ +6.38% | ▲ +6.85% | $4.12 (−48.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access